Regulatory requirements for nanotechnology-based RNA vaccines and therapeutics

Download CPI’s guide to regulatory requirements for nanotechnology-based RNA vaccines and therapeutics, including MHRA guidance and decision tools.

The Intracellular Drug Delivery Centre is a collaboration led by CPI with Medicines Discovery Catapult and three leading universities: University of Strathclyde, University of Liverpool, and Imperial College London.

The Centre aims to support the development of new drug delivery technologies for RNA payloads and advance promising RNA vaccines and therapeutics towards clinical application.

This quick-start guide provides a comprehensive roadmap to navigating the complex regulatory pathways for nanotechnology-based RNA vaccines and therapeutics, addressing the need for clear regulatory and quality data requirements. It also includes a decision tree, created by the MHRA, to help innovators understand relevant guidance documents and access support for bespoke interpretation.

For more information about the Intracellular Drug Delivery Centre please email juliana.haggerty@uk-cpi.com.

Get the guide

Related guides

A practical guide to using life cycle assessments (LCA) for sustainable process development

Coating technologies for fibre packaging

From bench to clinic: ten ways CPI de-risks and accelerates viral vector and viral vaccine development

A practical guide to using life cycle assessments (LCA) for sustainable process development

Coating technologies for fibre packaging

A practical guide to using life cycle assessments (LCA) for sustainable process development

Coating technologies for fibre packaging